Trimethylglycine

Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023

DEER PARK, Ill., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2023.

Key Points: 
  • DEER PARK, Ill., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2023.
  • Eton reported second quarter 2023 product sales and royalty revenue of $6.5 million, representing 175% growth over the prior year period and 22% growth over the first quarter of 2023.
  • Net Revenue: Net sales for the second quarter of 2023 were $12.0 million compared with $7.4 million in the prior year period.
  • As previously announced, Eton will host its second quarter 2023 conference call as follows:

Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)

Retrieved on: 
Wednesday, May 10, 2023

DEER PARK, Ill., May 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the commercial availability of Betaine Anhydrous for Oral Solution 180 grams for the treatment of homocystinuria.

Key Points: 
  • “We are excited to be offering a lower cost alternative1 to Cystadane while still providing full patient and provider support services.
  • Betaine Anhydrous is available exclusively through Optime Care, a specialty pharmacy dedicated to helping patients with rare diseases manage their conditions.
  • Optime Care will administer the Eton Cares Program in partnership with Eton Pharmaceuticals.
  • Betaine anhydrous for oral solution is indicated in children and adults for the treatment of homocystinuria to decrease high homocysteine blood levels.

Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results

Retrieved on: 
Thursday, March 16, 2023

DEER PARK, Ill., March 16, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2022.

Key Points: 
  • DEER PARK, Ill., March 16, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2022.
  • Eton reported fourth quarter 2022 product sales and royalty revenue of $3.5 million, representing 220% growth over the prior year and 9% growth over the third quarter of 2022.
  • The Company expects the sequential growth rate to increase in the first quarter of 2023 compared to the fourth quarter of 2022.
  • As previously announced, Eton Pharmaceuticals will host a its fourth quarter 2022 conference call as follows:

Oakrum Pharma and ANI Pharmaceuticals Announce the Launch of Betaine Anhydrous Powder, the first Generic Version of Cystadane® (betaine anhydrous for oral solution) Powder, Including 180 Days of Exclusivity

Retrieved on: 
Monday, February 14, 2022

Oakrum currently has licensing rights to seven additional ANDAs filed with the FDA and expects to file additional generic orphan drugs later this year."

Key Points: 
  • Oakrum currently has licensing rights to seven additional ANDAs filed with the FDA and expects to file additional generic orphan drugs later this year."
  • "Our collaboration with Oakrum furthers ANI's mission of bringing high-quality prescription pharmaceutical products to patients in need.
  • Oakrum Pharma is not responsible for updating events occurring after the date of this press release.
  • The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Rye is Healthy, Thanks to an Interplay of Microbes

Retrieved on: 
Monday, August 5, 2019

Rye sourdough used for the baking of rye bread is rich in lactic acid bacteria.

Key Points: 
  • Rye sourdough used for the baking of rye bread is rich in lactic acid bacteria.
  • The study found that gut microbes and microbes found in sourdough produce compounds that are partially the same.
  • However, gut microbes also produce derivatives of trimethylglycine, also known as betaine, contained in rye.
  • For instance, the so-called Rye Factor refers to the lower insulin response caused by rye than, for example, wheat bread.